https://www.thebodypro.com/tag/feature

Features

The Latest

aerial view of suburban neighborhood

Housing Is Important for Seniors, People Living With HIV, and Everyone Else

Doctors contemplate the role of housing in health care as people with HIV grow older, but are often poor.

strips of paper with headlines over microscope science background

Top 10 HIV Clinical Developments of 2019

Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.

Weight Gain and HIV Antiretrovirals photo illustration

Weight Gain and HIV Antiretrovirals: Lipodystrophy for the Integrase Era

In a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell.

Two-Drug TANGO photo illo

TANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the Year

Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?

F/TAF for PrEP photo illo

And Then There Were Two: FTC/TAF Is Also PrEP

Given similar efficacy and the renal and bone benefits, TAF/FTC should be favored over TDF/FTC. But as David Wohl, M.D., explains, the reality isn't so simple.

Dolutegravir and Pregnancy photo illo

Tsepamo Study Provides Critical Update on Neural Tube Defects and Dolutegravir

A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.

Long-Acting Antiretrovirals photo illo

ATLAS, FLAIR, and the Upcoming Arrival of Long-Acting Injectable HIV Treatment

The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?

Islatravir photo illo

Islatravir Is Potent and Long-Lasting -- and May Be Having an Identity Crisis

This is clearly an antiretroviral not built for daily administration. But then what is it destined for?

The DAWNING Study photo illo

DAWNING Study Casts New Light on the Details of Resistance

The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.

Doxycycline for STIs photo illo

Doxycycline for Bacterial STI Prevention: A Different Type of PrEP

An international team of experts conducted a thoughtful review of existing research regarding the use of doxycycline for STI prevention. Do the risks of its use outweigh the benefits?